Association of Treatment With Secukinumab With Exacerbation of Dermatomyositis in a Patient With Psoriasis

Perna, Danielle; Callen, Jeffrey P.; Schadt, Courtney R.

doi:10.1001/jamadermatol.2021.6011

Cited by 4 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cases of psoriasis concurrent with dermatomyositis are also occasionally seen in daily clinical practice. As far as we know, there have been limited instances documented in the literature ( Table 1 ) ( 12 – 23 ). In these cases, five were male and ten were female, of which six patients were under thirty years old, and they were all diagnosed with juvenile dermatomyositis.…”

Section: Discussionmentioning

confidence: 99%

“…Based on previous studies, we speculate that there seems to be a complex, interacting, and self-sustaining inflammatory circuit among these cytokines in psoriasis ( 5 ). However, drugs such as adalimumab and secukinumab can disrupt the balance of the inflammatory circuit, leading to the accumulation or dominance of certain cytokines within inflammatory circuit and ultimately resulting in the appearance of clinical symptoms of DM, even though this condition is relatively rare ( 16 , 23 ). As mentioned above, sunlight exposure may be a possible trigger for our patient.…”

Section: Discussionmentioning

confidence: 99%

“…TNF-α inhibitors such as adalimumab, IL-17 inhibitors such as secukinumab, are effective for psoriasis, and are frequently used worldwide. However, there are studies reporting dermatomyositis or psoriasis occurring or exacerbating after receiving these two therapies ( 16 , 23 ). And while TNF-α inhibitors may be a potential therapy for DM, the worsening of the disease can also be seen during treatment ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Concurrence of dermatomyositis and psoriasis: a case report and literature review

Chu,

Yang,

Niu

2024

Front. Immunol.

View full text Add to dashboard Cite

Dermatomyositis (DM) is a type of inflammatory myopathy with unknown causes. It is characterized by distinct skin lesions, weakness in the muscles close to the body, and the potential to affect multiple organs. Additionally, it may be associated with the presence of malignancies. The development of DM is influenced by genetic susceptibility, autoimmune response, and various external factors like cancer, drugs, and infectious agents. Psoriasis is a chronic, recurring, inflammatory, and systemic condition. Scaly erythema or plaque is the typical skin manifestation. The etiology of psoriasis involves genetic, immune, environmental and other factors. It is uncommon for a patient to have both of these diseases simultaneously, although individuals with DM may occasionally exhibit symptoms similar to those of psoriasis. Our patient was diagnosed with psoriasis in his 50s because of scalp squamous plaques, but he did not receive standard treatment. Ten years later, he developed symptoms of muscle pain and limb weakness. He was diagnosed with psoriasis complicated with dermatomyositis in our department and received corresponding treatment. Moreover, we reviewed the relevant literature to evaluate similarities and differences in clinical manifestation and treatment to other cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Concurrence of dermatomyositis and psoriasis: a case report and literature review

Chu,

Yang,

Niu

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Over 200 articles were found. After reviewing these articles, fourteen cases 2–13 were concluded ( Table 1 ). The treatment of these cases concluded methotrexate, corticosteroids, cyclosporin, ustekinumab, mycophenolate mofetil and azathioprine.…”

mentioning

confidence: 99%

JAK Inhibitors as Potential Therapeutic Strategy for the Dilemma of Psoriasis Concurrent with Dermatomyositis in the SARS-CoV-2 Era

Xu¹,

Xu²

2023

CCID

View full text Add to dashboard Cite

Dermatomyositis is a rare inflammatory disease with potentially life-threatening systemic involvement that is treated with systemic corticosteroids. However, when psoriasis coexists with dermatomyositis, the administration of corticosteroids may exacerbate psoriasis after withdrawal, posing a treatment dilemma. Our search of the literature revealed 14 cases where various treatments were used, including methotrexate, corticosteroids, cyclosporin, ustekinumab, mycophenolate mofetil, and azathioprine. While methotrexate showed promise, it carries risks, and corticosteroids were used despite their potential to exacerbate psoriasis. Based on transcriptomic data analysis of psoriasis and dermatomyositis, the type II interferon-mediated signaling pathway was enriched in both diseases. Medication targeting this pathway, such as JAK inhibitors, could be a potential solution for the psoriasis concurrent with dermatomyositis dilemma, as JAK inhibitors have been proven effective in treating both dermatomyositis and psoriasis, with some being FDA-approved for treating COVID-19. Therefore, JAK inhibitors may be a potential therapeutic strategy for psoriasis concurrent with dermatomyositis in the SARS-CoV-2 era.

show abstract

Biologic drugs in the treatment of juvenile dermatomyositis: a literature review

Sener,

Cam,

Ozen

et al. 2023

Clin Rheumatol

View full text Add to dashboard Cite

Association of Treatment With Secukinumab With Exacerbation of Dermatomyositis in a Patient With Psoriasis

Abstract: Author Contributions: Mr Kodumudi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Cited by 4 publications

References 7 publications

Concurrence of dermatomyositis and psoriasis: a case report and literature review

Concurrence of dermatomyositis and psoriasis: a case report and literature review

JAK Inhibitors as Potential Therapeutic Strategy for the Dilemma of Psoriasis Concurrent with Dermatomyositis in the SARS-CoV-2 Era

Biologic drugs in the treatment of juvenile dermatomyositis: a literature review

Contact Info

Product

Resources

About